Preclinical Regimen Identification

Chemical class: Various
Partners: Johns Hopkins University
Background

M.tb, the bacterium that causes TB, is remarkably adept at developing resistance to drugs and therefore active TB must be fought with combination therapy. Today’s four-drug first-line TB treatment evolved through the addition and substitution of drugs into the existing regimen. Novel combinations offer the promise to transform treatment. However, modifying TB treatment one drug at a time is too lengthy, expensive, and inefficient a process. Today, the emerging gold standard in TB drug development is a regimen-based approach by which multiple new agents are combined early in the development process to create new TB drug regimens with the potential to shorten and simplify TB treatment. This approach also shows promise to develop regimens that could be effective against both TB and drug-resistant forms of TB.

This program provided this preclinical evidence for PaMZ and regimens within the NC-003 trial, and continues to identify and rapidly advance the most promising combinations of potential new TB drugs to form future new regimens.This initiative seeks to promote regimen-based development by qualifying new preclinical models with better predictability for human disease. These new models could contribute to identifying optimized drug combinations and earlier registration and approval of new, improved, and safe TB drug regimens.

Preclinical Development